DG Alert: EMA Recommends Restricting Use of Multaq
DG Alert: European Medicines Agency has recommended restricting the use of dronedarone (Multaq) to only patients with paroxysmal or persistent atrial fibrillation due to an increased risk of liver, lung, and cardiovascular adverse events.